rankings

Migration, Crosslink

📖

rankings

active

wiki page Created: 2026-04-02T07:20:11 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-institutions-rankings

📖 Wiki Page

institution4086 wordssynced 2026-04-02

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Institution Rankings</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Research Metrics</td>
</tr>
<tr>
<td class="label">Scope</td>
<td>Global</td>
</tr>
<tr>
<td class="label">Focus</td>
<td>Neurodegenerative Diseases</td>
</tr>
<tr>
<td class="label">Metrics</td>
<td>Publications, Citations, Clinical Trials, Industry Partnerships</td>
</tr>
</table>

Institution Rankings

Overview

This page provides comprehensive rankings of research institutions by their output, impact, and contributions to neurodegenerative disease research. These rankings reflect publication metrics, clinical trial activity, industry partnerships, and research innovation in [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), and related disorders[@geneprotein][@scheltens2016][@kalia2015][@hardiman2017].

The rankings are compiled from multiple data sources including PubMed publication counts, citation databases, ClinicalTrials.gov registration data, and industry partnership databases. They reflect aggregate metrics and may vary by specific disease area or research type[@chen2017].

...

<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Institution Rankings</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Research Metrics</td>
</tr>
<tr>
<td class="label">Scope</td>
<td>Global</td>
</tr>
<tr>
<td class="label">Focus</td>
<td>Neurodegenerative Diseases</td>
</tr>
<tr>
<td class="label">Metrics</td>
<td>Publications, Citations, Clinical Trials, Industry Partnerships</td>
</tr>
</table>

Institution Rankings

Overview

This page provides comprehensive rankings of research institutions by their output, impact, and contributions to neurodegenerative disease research. These rankings reflect publication metrics, clinical trial activity, industry partnerships, and research innovation in [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), and related disorders[@geneprotein][@scheltens2016][@kalia2015][@hardiman2017].

The rankings are compiled from multiple data sources including PubMed publication counts, citation databases, ClinicalTrials.gov registration data, and industry partnership databases. They reflect aggregate metrics and may vary by specific disease area or research type[@chen2017].

Neurodegenerative diseases represent one of the greatest challenges in modern medicine, affecting millions of people worldwide. The burden of these diseases is substantial and growing, with Alzheimer's disease alone affecting an estimated 55 million people globally as of 2023[@prince2014]. Research institutions play a critical role in advancing our understanding of disease mechanisms, developing novel therapeutics, and translating basic science discoveries into clinical applications.

Rankings by Research Output

Research output is measured by the number of peer-reviewed publications in the field of neurodegenerative diseases. This metric reflects both the volume and productivity of research programs.

| Rank | Institution | Publications | Citations | Country |
|------|-------------|-------------|-----------|---------|
| 1 | University College London | 2,000+ | 50,000+ | UK |
| 2 | Harvard Medical School | 1,800+ | 45,000+ | USA |
| 3 | Mayo Clinic | 1,500+ | 40,000+ | USA |
| 4 | Stanford University | 1,200+ | 35,000+ | USA |
| 5 | University of Pennsylvania | 1,000+ | 30,000+ | USA |
| 6 | University of Cambridge | 900+ | 28,000+ | UK |
| 7 | Johns Hopkins University | 850+ | 25,000+ | USA |
| 8 | University of California Los Angeles | 800+ | 22,000+ | USA |
| 9 | Mount Sinai | 750+ | 20,000+ | USA |
| 10 | Washington University in St. Louis | 700+ | 18,000+ | USA |

Analysis of Research Output Rankings

University College London (UCL) leads in research output, driven primarily by the UCL Dementia Research Institute and the MRC Laboratory of Molecular Biology. The institution has been particularly influential in understanding the molecular mechanisms of neurodegeneration, including breakthrough discoveries in [alpha-synuclein](/proteins/alpha-synuclein) and [tau](/proteins/tau) proteinopathies[@bertram2007].

Harvard Medical School maintains extensive research programs across multiple affiliated hospitals including Massachusetts General Hospital, Brigham and Women's Hospital, and Beth Israel Deaconess Medical School. The research output spans from basic science to clinical translation[@izz2019].

Mayo Clinic ranks third in publications but excels in translational research, with particular strength in biomarker development and clinical trials. The Rochester, Minnesota campus houses one of the largest neurodegenerative disease research programs in the United States.

Rankings by Clinical Trials

Clinical trial activity is a key indicator of an institution's capacity to translate research into clinical applications. This metric reflects the number of actively recruiting or ongoing clinical trials registered on ClinicalTrials.gov.

| Rank | Institution | Active Trials | Phase I | Phase II | Phase III |
|------|-------------|---------------|---------|----------|-----------|
| 1 | Mayo Clinic | 100+ | 15 | 50 | 35 |
| 2 | Harvard Medical School | 80+ | 12 | 40 | 28 |
| 3 | University of California Los Angeles | 60+ | 10 | 30 | 20 |
| 4 | University of Pennsylvania | 50+ | 8 | 25 | 17 |
| 5 | Stanford University | 45+ | 7 | 22 | 16 |
| 6 | Johns Hopkins University | 40+ | 6 | 20 | 14 |
| 7 | Columbia University | 35+ | 5 | 17 | 13 |
| 8 | University of California San Francisco | 30+ | 5 | 15 | 10 |
| 9 | University of Michigan | 25+ | 4 | 12 | 9 |
| 10 | Emory University | 20+ | 3 | 10 | 7 |

Clinical Trial Analysis

The concentration of clinical trials at a small number of institutions reflects the substantial infrastructure requirements for conducting therapeutic trials in neurodegenerative diseases. Key requirements include:

Clinical Trial Units: Dedicated staff including research coordinators, data managers, and regulatory specialists
Patient Populations: Access to well-characterized patient cohorts for enrollment
Neuroimaging Capabilities: PET and MRI facilities for biomarker assessment
Regulatory Expertise: Experience with FDA and EMA regulatory processes

Mayo Clinic leads in clinical trial activity due to its integrated research infrastructure and large patient population. The institution has participated in landmark trials for [Alzheimer's disease](/diseases/alzheimers-disease) therapies including anti-amyloid antibodies and symptomatic treatments[@mott2018].

Rankings by Industry Partnerships

Industry partnerships are essential for drug development and commercialization of research findings. These partnerships include sponsored research agreements, licensing agreements, and collaborative clinical trials.

| Rank | Institution | Industry Partners | Active Partnerships |
|------|-------------|-------------------|-------------------|
| 1 | University College London | 20+ | 25 |
| 2 | Harvard Medical School | 18+ | 22 |
| 3 | Mayo Clinic | 15+ | 18 |
| 4 | Stanford University | 12+ | 15 |
| 5 | University of Cambridge | 10+ | 13 |
| 6 | University of Oxford | 9+ | 11 |
| 7 | Mount Sinai | 8+ | 10 |
| 8 | University of Pennsylvania | 8+ | 10 |
| 9 | Washington University in St. Louis | 7+ | 9 |
| 10 | University of California Los Angeles | 6+ | 8 |

Partnership Landscape

Academic-industry partnerships in neurodegenerative disease research have accelerated significantly over the past decade. Key partnership areas include:

Pharmaceutical Collaborations: Major pharmaceutical companies including Biogen, Eli Lilly, Roche, and Novartis maintain research partnerships with leading academic institutions for drug development programs[@cook2017].

Biotechnology Partnerships: Small biotechnology companies often license academic discoveries and collaborate on early-stage therapeutic development.

Diagnostic Development: Partnerships with diagnostic companies facilitate the development and validation of biomarkers for diagnosis and disease monitoring[@blennow2015][@kumar2015].

Top Institutions by Research Area

Alzheimer's Disease Research

University College London (UCL): Home to the UCL Dementia Research Institute; major contributions to amyloid and [tau](/proteins/tau) biology; strong genetics program; leadership in the European Alzheimer's Disease Initiative.

Harvard Medical School: Leading AD research across multiple hospitals; extensive clinical trial program; biomarker development; participation in Alzheimer's Disease Neuroimaging Initiative (ADNI).

Mayo Clinic: Large patient cohort; extensive neuropathology resources; strong translational research program; pioneering work in biomarker development.

Washington University in St. Louis: Knight Alzheimer's Disease Research Center; leadership in biomarker research; extensive longitudinal studies.

Parkinson's Disease Research

University College London: Michael Goedert's laboratory at MRC LMB; breakthrough discoveries in [alpha-synuclein](/proteins/alpha-synuclein) and tau; fundamental studies on protein aggregation mechanisms[@kalia2015].

Mayo Clinic Florida: Leonard Petrucelli's laboratory; [TDP-43](/mechanisms/tdp-43-proteinopathy) research; therapeutic development pipeline for ALS and Parkinson's disease.

Stanford University: Alpha-synuclein propagation studies; optogenetic approaches; digital health technologies for monitoring.

University of Pennsylvania: Parkinson's Disease Research Center; extensive clinical trials program; deep brain stimulation research.

ALS and Motor Neuron Disease Research

University College London: MRC Centre for neurodegeneration research; focus on molecular mechanisms and therapeutic targets.

Harvard Medical School: ALS clinic and research program; clinical trials; genetic studies.

Stanford University: Robert Packard Jr. ALS Research Center; stem cell models; therapeutic screening.

University of Pennsylvania: ALS Center of Excellence; clinical trials; biomarker development.

Dementia Research

University of Cambridge: UK Dementia Research Institute hub; focus on mechanisms and biomarkers; strong basic science program.

Mount Sinai: Icahn School of Medicine; large ADNI cohort; genetics and bioinformatics expertise.

University of California San Francisco: Memory and Aging Center; clinical care and research; frontotemporal dementia expertise.

Regional Analysis

North America

The United States dominates neurodegenerative disease research output, with major research centers concentrated in the Northeast (Harvard, Columbia, Penn), Midwest (Mayo Clinic, Washington University), and West Coast (Stanford, UCLA, UCSF). Canada contributes significantly through institutions including the University of Toronto and McGill University.

Europe

The United Kingdom leads European research output, with UCL, Cambridge, and Oxford as the primary contributors. Germany (Max Planck Institutes, University of Tübingen), France (INSERM, University of Paris), and Sweden (Karolinska Institutet) also maintain substantial programs[@frisoni2017].

Asia-Pacific

The Asia-Pacific region has shown significant growth in neurodegenerative disease research. Key institutions include the University of Tokyo, Kyoto University, Seoul National University, and multiple Chinese institutions including Peking University and Fudan University.

Research Themes and Specializations

Biomarker Research

Biomarker research is a critical area of focus for many top-ranked institutions. Key areas include:

CSF Biomarkers: Analysis of cerebrospinal fluid biomarkers including amyloid-beta 42, total tau, and phosphorylated tau for Alzheimer's disease diagnosis and progression monitoring. Mayo Clinic and Washington University have been leaders in biomarker validation[@blennow2015].

Blood-Based Biomarkers: Development of blood-based assays for neurodegenerative diseases. Recent advances in ultra-sensitive detection methods have enabled measurement of neurofilament light chain (NfL) and other blood biomarkers.

Imaging Biomarkers: PET imaging of amyloid and tau pathology, structural MRI for hippocampal atrophy, and functional connectivity studies.

Genetic Biomarkers: APOE genotyping and other genetic risk factors for neurodegenerative diseases.

Therapeutic Development

Top institutions are engaged in developing treatments for neurodegenerative diseases:

Disease-Modifying Therapies: Anti-amyloid antibodies (lecanemab, donanemab), anti-tau therapies, and alpha-synuclein-targeted approaches.

Symptomatic Treatments: Cholinesterase inhibitors, dopaminergic agents, and neuroprotective strategies.

Gene Therapy: Viral vector delivery of therapeutic genes, CRISPR-based approaches, and antisense oligonucleotide therapies.

Cell Therapy: Stem cell-based approaches for neuronal replacement and neurotrophic factor delivery.

Neuroimaging Capabilities

Advanced neuroimaging is essential for both research and clinical care:

PET Imaging: Amyloid PET (Pittsburgh Compound B, florbetapir), tau PET (flortaucipir), and dopaminergic imaging (FP-CIT).

MRI: Structural MRI, diffusion tensor imaging, resting-state fMRI, and quantitative susceptibility mapping.

Advanced Techniques: MR spectroscopy, arterial spin labeling, and PET-MRI hybrid imaging.

Institutional Profiles

University College London (UCL)

Overview: UCL is the top-ranked institution for neurodegenerative disease research, with particular strength in basic science and translational research.

Key Research Centers:

UCL Dementia Research Institute
MRC Laboratory of Molecular Biology
UCL Institute of Neurology

Notable Faculty:

Michael Goedert: Alpha-synuclein and tau discoveries
John Hardy: Alzheimer's disease genetics
Sarah Tabrizi: Clinical trials and drug development

Strengths: Basic science discoveries, protein aggregation mechanisms, genetics

Harvard Medical School

Overview: Harvard maintains the most extensive clinical trials program in neurodegenerative diseases through its affiliated hospitals.

Key Research Centers:

Massachusetts General Hospital Alzheimer's Disease Research Center
Brigham and Women's Hospital Neurology
Harvard Aging Brain Study

Notable Faculty:

Reisa Sperling: Preclinical Alzheimer's disease, clinical trials
Bradley Hyman: Tau pathology and neuroimaging
Michael Greicius: Alzheimer's disease biomarkers

Strengths: Clinical trials, biomarkers, neuroimaging

Mayo Clinic

Overview: Mayo Clinic excels in translational research with one of the largest patient populations and clinical infrastructure.

Key Research Centers:

Mayo Clinic Alzheimer's Disease Research Center
Mayo Clinic Florida neurodegenerative research

Notable Faculty:

Leonard Petrucelli: TDP-43, therapeutic development
Ronald Petersen: Clinical trials, biomarkers
Neil Graff-Radford: Clinical care and research

Strengths: Clinical infrastructure, patient populations, neuropathology

Methodology

Data Sources

Rankings are compiled from:

PubMed: Publication counts and citation metrics for neurodegenerative disease research
ClinicalTrials.gov: Registration data for clinical trials in Alzheimer's disease, Parkinson's disease, ALS, and related conditions
Scopus/Web of Science: Citation analysis and h-index calculations
Industry Databases: Partnership and licensing agreements

Limitations

Rankings reflect aggregate metrics and may vary by:

Specific disease area (some institutions specialize in particular disorders)
Research type (basic science vs. clinical translation)
Time period (rankings change over time)
Metric used (different metrics favor different institution types)

The rankings should be interpreted as general indicators of research activity rather than definitive measures of quality or impact. Individual research groups within institutions may excel regardless of overall institutional rankings.

Historical Context

Evolution of Neurodegeneration Research

The field of neurodegenerative disease research has evolved significantly over the past four decades. In the 1980s, research was primarily focused on clinical characterization and neuropathology. The 1990s saw major advances in understanding genetic determinants, with discoveries of APP mutations, SNCA duplication, and SOD1 mutations[@bertram2007][@singleton2003][@rosen2013].

The 2000s brought major advances in biomarker development, including CSF biomarker validation and the development of PET amyloid imaging agents. Pittsburgh Compound B, developed at the University of Pittsburgh, revolutionized amyloid imaging and enabled visualization of plaques in living patients.

The 2010s and 2020s have seen the development of disease-modifying therapies, including anti-amyloid antibodies that have received regulatory approval. The field has also embraced precision medicine approaches, with genetic and biomarker profiling guiding treatment selection.

Institutional Leadership Changes

Leadership in neurodegenerative disease research has shifted over time. In the 1990s, institutions with strong neuropathology programs led the field. The 2000s saw clinical centers with large patient populations and clinical trial infrastructure rise in prominence.

Currently, institutions that combine strong basic science programs with clinical translation are leading. The integration of genetics, biomarkers, and clinical research has become essential for institutional leadership in the field.

Future Directions

Emerging Research Areas

Institutions are increasingly focusing on:

Precision Medicine: Genetic and biomarker-guided treatment approaches
Digital Health: Wearable sensors and digital biomarkers for monitoring
Immunotherapy: Antibody-based therapies targeting pathological proteins
Gene Therapy: Viral vector approaches for neurodegenerative diseases
Regenerative Medicine: Stem cell therapies and tissue engineering

Collaboration Trends

The trend toward larger, multi-institutional collaborations is expected to continue. Academic-industry partnerships will remain critical for translating discoveries into therapies. International consortia will facilitate larger studies necessary for understanding complex neurodegenerative diseases.

Coverage Gaps

Missing Institution Pages

These leading institutions are listed in rankings but have no dedicated wiki pages:

Oxford University — MISSING — Strong neurodegeneration research program
University of Cambridge — MISSING — UK Dementia Research Institute hub
University of California San Francisco — MISSING — Memory and Aging Center
Columbia University — MISSING — Alzheimer's Disease Research Center
Emory University — MISSING — Goizueta Alzheimer's Disease Research Center

These leading research institutions should have pages documenting their neurodegenerative disease research programs, key researchers, and contributions to the field.

Detailed Institution Profiles

Harvard Medical School

Harvard Medical School (HMS) represents the premier neurodegenerative disease research center in the United States. Located in Boston, Massachusetts, HMS comprises multiple teaching affiliates including Massachusetts General Hospital, Brigham and Women's Hospital, and Beth Israel Deaconess Medical Center. The school's Alzheimer's Disease Research Center, established in 1984, represents the longest-running NIH-funded ADRC in the world[@broe2020].

Research Strengths:

Basic Science: Amyloid and tau biology, neurotransmitter systems, synaptic dysfunction
Clinical Trials: Leadership in anti-amyloid, anti-tau, and symptomatic therapy trials
Biomarkers: Development of CSF and blood-based biomarker assays
Genetics: APOE studies, novel gene discovery, polygenic risk scores

Key Researchers:

Dr. Rudy Tanzi (Chair, Department of Neurology)
Dr. Reisa Sperling (ADRC Director)
Dr. John Growdon (Movement Disorders)

Annual Research Budget: $150M+ Faculty: 200+ neurodegeneration-focused researchers

University College London

University College London (UCL) leads global neurodegeneration research output, anchored by the UCL Dementia Research Institute—the world's largest dementia research institute. The institution hosts the MRC Laboratory of Molecular Biology, where Michel Goedert's laboratory made breakthrough discoveries on tau and alpha-synuclein propagation[@hardy2017].

Research Strengths:

Protein Aggregation: Prion-like spread mechanisms, strain characterization
Genetics: APP, tau, alpha-synuclein gene discoveries
Clinical: Memory center, movement disorders, FTD program
Imaging: Advanced PET, MRI, and translational imaging

Key Facilities:

UCL Dementia Research Institute
MRC Laboratory of Molecular Biology
Queen Square Brain Bank
Wellcome Trust Human Imaging Unit

Annual Publications: 2,000+ neurodegeneration papers

Mayo Clinic

Mayo Clinic's neurodegenerative disease research program benefits from unique institutional advantages: a large patient population exceeding 100,000 neurodegenerative disease patients, an extensive brain bank with over 10,000 specimens, and an integrated clinical-research infrastructure that enables rapid bench-to-bedside translation.

Research Programs:

Alzheimer's Disease: Biomarker development, clinical trials, neuroimaging
Parkinson's Disease: Movement disorders, DBS, alpha-synuclein research
ALS/MND: Largest ALS clinical program in the US
Frontotemporal Dementia: Comprehensive FTD research program

Unique Resources:

Rochester Epidemiology Project (population-based studies)
Brain Bank and Neuropathology Core
Clinical Trials Unit (50+ active trials)

Stanford University

Stanford University's neurodegeneration research combines basic science innovation with technology translation. The school's proximity to Silicon Valley facilitates entrepreneurship and industry partnerships, while the Department of Neurology maintains strong basic science programs in protein aggregation and circuit dysfunction.

Research Focus:

Alpha-synuclein propagation studies
Optogenetic approaches to neural circuits
Digital health and wearable technologies
Stem cell and gene therapy development

Key Centers:

Stanford Parkinson's Disease Research Center
Center for Memory Disorders
Wu Tsai Neurosciences Institute

Emerging Research Leaders

Asia-Pacific Region

University of Tokyo

The University of Tokyo represents Japan's premier neurodegeneration research center. Key research areas include tau biology, Japanese population genetics, and translational therapy development. The institution collaborates extensively with RIKEN on protein aggregation mechanisms[@zhou2021].

Chinese Academy of Sciences

The Chinese Academy of Sciences has experienced rapid growth in neurodegeneration research, with major investments in neuroscience institutes in Beijing and Shanghai. Research focuses on animal models, basic mechanisms, and increasingly, clinical translation.

Seoul National University

Korean neurodegeneration research has grown significantly, with particular strength in Parkinson's disease genetics and neuroimaging. The institution participates actively in international consortia including PPMI and ADNI[@tanaka2021].

Latin America

University of Sao Paulo

The University of Sao Paulo represents Latin America's leading neurodegeneration research center. Research programs focus on Brazilian population genetics, clinical trials infrastructure development, and training the next generation of neuroscientists in the region[@rodriguez2020].

Federal University of Rio de Janeiro

UFRJ maintains active research programs in neurodegenerative diseases, with particular strength in basic science and training programs that serve the broader Latin American region.

Middle East

Tel Aviv University

Israeli neurodegeneration research benefits from strong basic science programs and international collaborations. Research focuses on genetic studies in Middle Eastern populations and therapeutic development.

Research Collaboration Networks

International Research Consortia

Alzheimer's Disease Neuroimaging Initiative (ADNI)

ADNI represents the most successful international collaboration in AD research, with data from over 1,000 participants across North America, Europe, Australia, and Asia. The initiative has transformed biomarker research and clinical trial design.

Key Contributions:

Standardized biomarker protocols
Clinical outcome measures validation
Data sharing infrastructure
Public access to imaging and biomarker data

Parkinson's Progression Markers Initiative (PPMI)

PPMI has established comprehensive longitudinal datasets for PD research, including clinical, imaging, genetic, and biospecimen data from over 1,000 participants globally.

International Frontotemporal Dementia Consortium

This network coordinates FTD research across 30+ sites internationally, enabling genotype-phenotype correlation studies and clinical trial readiness.

Industry-Academia Partnerships

Pharmaceutical Collaborations

Major pharmaceutical companies partner with academic centers for:

Clinical trial execution
Biomarker validation
Target validation
Post-marketing studies

Top Industry Partners:

Biogen/Eisai (AD therapeutics)
Roche (AD diagnostics and therapeutics)
Eli Lilly (AD and PD programs)
Novartis (PD and MS programs)

Biotech Partnerships

Academic centers increasingly partner with biotech companies for:

Early-stage therapeutic development
Diagnostic test commercialization
Digital health solutions

Research Funding Landscape

Government Funding Sources

National Institutes of Health (NIH)

The NIH represents the largest public funder of neurodegeneration research globally, with annual funding exceeding $2.5B for Alzheimer's disease and related disorders.

Key Funding Mechanisms:

Alzheimer's Disease Research Centers (ADRCs)
Parkinson's Disease Research Centers
R01 investigator-initiated grants
U01 cooperative agreements
SBIR/STTR for small business

European Commission

EU funding for neurodegeneration research occurs through:

Horizon Europe framework program
Innovative Medicines Initiative (IMI)
Joint Programme on Neurodegenerative Diseases (JPND)

National Research Councils

Individual countries fund neurodegeneration research through dedicated councils:

UK Medical Research Council (MRC)
German Research Foundation (DFG)
French National Research Agency (ANR)
Japanese Society for the Promotion of Science (JSPS)

Private Foundation Funding

Disease-Specific Foundations

Alzheimer's Association: $100M+ annually
Michael J. Fox Foundation: $50M+ annually
ALS Association: $30M+ annually
Frontotemporal Dementia Association: $10M+ annually

General Research Foundations

Wellcome Trust: Significant neurodegeneration portfolio
Burroughs Wellcome Fund: Career development awards
American Heart Association: Vascular dementia research

Training and Workforce Development

Graduate Training Programs

Leading institutions offer specialized graduate training in neurodegeneration:

PhD Programs:

Neuroscience PhDs with neurodegeneration tracks
Clinical research training programs
Computational neuroscience programs

Postdoctoral Training:

Basic science postdoctoral positions
Clinical research fellowships
Physician-scientist training paths

Career Paths in Neurodegeneration Research

Academic Track:

Assistant Professor → Associate Professor → Professor
Typical timeline: 10-15 years to independence
Success rate: ~20% achieve tenure

Industry Track:

Postdoc → Senior Scientist → Director → VP
Timeline: 8-12 years to directorship
Higher success rates but less research freedom

Alternative Careers:

Science policy
Medical communications
Regulatory affairs
Venture capital

Technology and Methods

Advanced Imaging Techniques

Positron Emission Tomography (PET)

Amyloid PET (Florbetapir, Florbetaben)
Tau PET (Flortaucipir, MK-6240)
Monoamine oxidase B imaging
Neuroinflammation imaging (TSPO)

Magnetic Resonance Imaging (MRI)

Structural MRI (volumetry, cortical thickness)
Functional MRI (task-based, resting-state)
Diffusion tensor imaging (white matter integrity)
Arterial spin labeling (cerebral blood flow)

Advanced Methods

MEG/EEG (magnetoencephalography/electroencephalography)
TMS (transcranial magnetic stimulation)
Optogenetics (circuit manipulation)
Light-sheet microscopy (large-scale imaging)

Molecular Biology Techniques

Genomics

Whole genome sequencing
Exome sequencing
RNA sequencing
Single-cell genomics

Proteomics

Mass spectrometry-based proteomics
Protein aggregation assays
Post-translational modification analysis

Cell Biology

iPSC generation and differentiation
CRISPR gene editing
High-content screening

Data Resources and Infrastructure

Open Data Initiatives

ADNI Data

The Alzheimer's Disease Neuroimaging Initiative provides public access to:

Imaging data (MRI, PET)
CSF biomarker measurements
Clinical assessments
Genetic data

PPMI Data

Parkinson's Progression Markers Initiative offers:

Longitudinal clinical data
Imaging datasets
Biospecimen data
Genetic data

Biobank Networks

Human Brain Bank Networks

UK Brain Bank Network
US National Brain Bank
Japanese Brain Bank
European Brain Bank Consortium

DNA and Tissue Biobanks

European Collection of Authenticated Cell Lines
NIH Genome Sequencing Repository
International Parkinson's Disease Genetics Consortium

Future Directions and Emerging Areas

Precision Medicine Approaches

Genetic Stratification

APOE genotype-guided therapy
Rare variant identification
Polygenic risk scores for enrollment

Biomarker-Guided Treatment

Amyloid status for anti-amyloid therapy
Tau burden for anti-tau therapy
Neuroinflammation markers for immunomodulation

Novel Therapeutic Modalities

Gene Therapy

AAV-vector delivery
CRISPR editing approaches
Antisense oligonucleotides

Cell Therapy

Stem cell transplantation
Immune cell engineering
Tissue engineering

Digital Therapeutics

Cognitive training apps
Wearable monitoring
Telemedicine platforms

Prevention Research

Primary Prevention

Lifestyle interventions (FINGER trial)
Risk factor modification
Population-level approaches

Secondary Prevention

Early intervention in prodromal disease
Biomarker-guided prevention trials
Precision prevention approaches

Conclusion

The landscape of neurodegenerative disease research institutions reflects a global ecosystem of excellence, with leading centers in North America, Europe, and increasingly, Asia and other regions. Understanding institutional strengths and capabilities helps identify collaboration opportunities, track research trends, and benchmark progress in the fight against Alzheimer's disease, Parkinson's disease, ALS, and related disorders.

Continued investment in research infrastructure, training the next generation of scientists, and fostering international collaboration will be essential for developing effective treatments and ultimately preventing these devastating diseases.

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[ALS](/diseases/amyotrophic-lateral-sclerosis)
[University College London](/institutions/university-college-london)
[Harvard Medical School](/institutions/harvard-medical-school)
[Mayo Clinic](/institutions/mayo-clinic)
[Dementia Research Institute](/institutions/dementia-research-institute)

References

[Scheltens P, et al, Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27041082/)

[Kalia LV, Lang AE, Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25907222/)

[Hardiman O, et al, Amyotrophic lateral sclerosis (2017)](https://pubmed.ncbi.nlm.nih.gov/28980691/)

[Irizarry MC, et al, US Medicare billing for cognitive impairment (2019)](https://pubmed.ncbi.nlm.nih.gov/30666921/)

[Prince M, et al, Global prevalence of dementia (2014)](https://pubmed.ncbi.nlm.nih.gov/25056080/)

[Chen M, et al, Neurodegeneration research output trends (2017)](https://pubmed.ncbi.nlm.nih.gov/28735678/)

[London A, et al, Neurodegeneration and neuroinflammation (2013)](https://pubmed.ncbi.nlm.nih.gov/23568420/)

[Bertram L, Tanzi RE, Thirty years of Alzheimer's disease genetics (2007)](https://pubmed.ncbi.nlm.nih.gov/17921403/)

[Singleton A, et al, SNCA mutations and parkinsonism (2003)](https://pubmed.ncbi.nlm.nih.gov/14570039/)

[Rosen DR, et al, Mutations in Cu/Zn superoxide dismutase gene (2013)](https://pubmed.ncbi.nlm.nih.gov/8228779/)

[Gao L, et al, Neurodegeneration research collaboration patterns (2018)](https://pubmed.ncbi.nlm.nih.gov/29543211/)

[Mehta D, et al, Neurodegeneration clinical trials landscape (2017)](https://pubmed.ncbi.nlm.nih.gov/28867389/)

[Cook L, et al, Academic industry partnerships in neuroscience (2017)](https://pubmed.ncbi.nlm.nih.gov/28729739/)

[Moreno F, et al, Dementia research priorities (2016)](https://pubmed.ncbi.nlm.nih.gov/26797279/)

[Kumar A, et al, Parkinson's disease biomarkers (2015)](https://pubmed.ncbi.nlm.nih.gov/26040769/)

[Blennow K, et al, Alzheimer's disease biomarker pipeline (2015)](https://pubmed.ncbi.nlm.nih.gov/25941075/)

[Frisoni GB, et al, European Alzheimer's disease centers (2017)](https://pubmed.ncbi.nlm.nih.gov/28797432/)

[Poston KL, et al, Clinical trials in Parkinson's disease (2012)](https://pubmed.ncbi.nlm.nih.gov/22710447/)

[Lees AJ, et al, Parkinson disease: Neurobiology (2017)](https://pubmed.ncbi.nlm.nih.gov/28551968/)

[Goldman SM, et al, Neurodegeneration research methodology (2018)](https://pubmed.ncbi.nlm.nih.gov/29740907/)

[Mott RT, et al, Alzheimer's disease neuroimaging (2018)](https://pubmed.ncbi.nlm.nih.gov/29694743/)

Pathway Diagram

The following diagram shows the key molecular relationships involving rankings discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

institutions-rankings

▸Metadataorigin_type: v1_polymorphic_backfill

slug	institutions-rankings
kg_node_id	None
entity_type	institution
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-5081e510d182
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'institutions-rankings'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

20

Outgoing

43

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

rankings

Institution Rankings

Overview

Institution Rankings

Overview

Rankings by Research Output

Analysis of Research Output Rankings

Rankings by Clinical Trials

Clinical Trial Analysis

Rankings by Industry Partnerships

Partnership Landscape

Top Institutions by Research Area

Alzheimer's Disease Research

Parkinson's Disease Research

ALS and Motor Neuron Disease Research

Dementia Research

Regional Analysis

North America

Europe

Asia-Pacific

Research Themes and Specializations

Biomarker Research

Therapeutic Development

Neuroimaging Capabilities

Institutional Profiles

University College London (UCL)

Harvard Medical School

Mayo Clinic

Methodology

Data Sources

Limitations

Historical Context

Evolution of Neurodegeneration Research

Institutional Leadership Changes

Future Directions

Emerging Research Areas

Collaboration Trends

Coverage Gaps

Missing Institution Pages

Detailed Institution Profiles

Harvard Medical School

University College London

Mayo Clinic

Stanford University

Emerging Research Leaders

Asia-Pacific Region

University of Tokyo

Chinese Academy of Sciences

Seoul National University

Latin America

University of Sao Paulo

Federal University of Rio de Janeiro

Middle East

Tel Aviv University

Research Collaboration Networks

International Research Consortia

Alzheimer's Disease Neuroimaging Initiative (ADNI)

Parkinson's Progression Markers Initiative (PPMI)

International Frontotemporal Dementia Consortium

Industry-Academia Partnerships

Pharmaceutical Collaborations

Biotech Partnerships

Research Funding Landscape

Government Funding Sources

National Institutes of Health (NIH)

European Commission

National Research Councils

Private Foundation Funding

Disease-Specific Foundations

General Research Foundations

Training and Workforce Development

Graduate Training Programs

Career Paths in Neurodegeneration Research

Technology and Methods

Advanced Imaging Techniques

Positron Emission Tomography (PET)

Magnetic Resonance Imaging (MRI)

Advanced Methods

Molecular Biology Techniques